All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): 4D-125
Therapeutic Area: Genetic Disease Product Name: 4D-125
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2020
Details:
4D-125 is an AAV gene therapy with an optimized and proprietary vector designed to deliver a functional copy of the RPGR gene to photoreceptors in the retina.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): 4D-310
Therapeutic Area: Genetic Disease Product Name: 4D-310
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 13, 2020
Details:
FDA has granted Fast Track designation to 4D-310 for Fabry disease. 4D-310 is a gene medicine engineered with a proprietary optimized AAV capsid discovered by 4DMT through its proprietary Therapeutic Vector Evolution platform.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): 4D-110
Therapeutic Area: Genetic Disease Product Name: 4D-110
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020
Details:
First patient has been dosed in the Phase 1 clinical trial of 4D-110, a Roche-licensed product candidate, delivered by a single intravitreal injection for Choroideremia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): 4D-710
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: 4D-710
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cystic Fibrosis Foundation
Deal Size: $14.0 million Upfront Cash: Undisclosed
Deal Type: Agreement June 17, 2020
Details:
Under this agreement, the CF Foundation will support the completion of IND-enabling research and development activities, and the planned Phase 1/2 clinical study of 4D-710, 4DMT’s wholly-owned product candidate for the aerosol treatment of CF lung disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): 4D-310
Therapeutic Area: Genetic Disease Product Name: 4D-310
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Viking Global Investors
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing June 16, 2020
Details:
Funds to be used to advance 3 precision-guided AAV gene therapy candidates through initial clinical proof-of-concept, to advance pre-clinical product pipeline, proprietary next-generation Therapeutic Vector Evolution platform, and to expand GMP manufacturing capabilities.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): 4D-310
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2020
Details:
Oral presentations to include data on 4D-310 Product Candidate for Fabry Disease and 4D-A101 Aerosol Vector for Cystic Fibrosis and other Lung Diseases.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
